LOW-DOSE SUBCUTANEOUS RECOMBINANT ERYTHROPOIETIN IN CHILDREN WITH CHRONIC-RENAL-FAILURE

被引：25

作者：

BURKE, JR

机构：

[1] Princess Alexandra Hospital, Brisbane

来源：

PEDIATRIC NEPHROLOGY | 1995年 / 9卷 / 05期

关键词：

LOW-DOSE SUBCUTANEOUS RECOMBINANT ERYTHROPOIETIN; CHRONIC RENAL FAILURE;

D O I：

10.1007/BF00860930

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

In a multicentre trial, low-dose subcutaneous recombinant human erythropoietin (r-Hu EPO) was evaluated in 22 children aged 4 months to 16 years with anaemia of chronic renal failure over a 12-month period. A starting dosage of 50 U/kg twice weekly was given until a target haemoglobin of 9-11 g/dl was achieved. The dosage was increased by 50 U/kg per week, each 4 weeks, if the haemoglobin did not increase by 1 g/dl per month. When the target haemoglobin was achieved, the same weekly dosage was given as a single injection. After 10 weeks, the mean haemoglobin increased from 6.7 +/- 0.7 to 9.6 +/- 1.9 g/dl (P < 0.001) and the haematocrit from 19.8% +/- 2.4% to 29.3% +/- 6.3% (P < 0.001). By 4 months the target haemoglobin was achieved in 19 patients on 50 U/kg twice weekly and 1 patient on 75 U/kg twice weekly. Two children with severe renal osteodystrophy failed to respond to 95 U/kg and 150 U/kg twice weekly. The maintenance weekly dose of r-Hu EPO in 9 children over 4-12 months ranged between 45 and 125 U/kg. The Wechsler intelligence score increased in II children from 92 +/- 16 to 97 +/- 17 over the 12-month period (P = 0.007). No adverse effects were recorded. A starting dose of r-Hu EPO of 50 U/kg subcutaneously twice weekly is recommended as effective and safe for the majority of children with anaemia of chronic renal failure.

引用

页码：558 / 561

页数：4

共 16 条

[1]

Walter T., De Andrala T., Chadud P., Perales G., Iron deficient anaemia: adverse effects on infant psychomotor development, Pediatrics, 84, pp. 7-17, (1989)

[2]

Eschbach J.W., Adaon J.W., Anaemia of end stage renal disease, Kidney Int, 28, pp. 1-50, (1985)

[3]

Winearls C.G., Oliver D.O., Pippard M.J., Reid C., Downing M., Cotes P.M., Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic dialysis, Lancet, 2, pp. 1176-1178, (1986)

[4]

Adaon J.W., Eschbach J.W., Management of the anaemia of chronic renal failure with recombinant erythropoietin, Q J Med, 272, pp. 1093-1101, (1989)

[5]

Montem G., Zacchello G., Baraldi E., Zancanato S., Suppiej A., Fabris F., Andretta B., Pavanello L., Zachello F., Benefits and risks of anaemic correction with recombinant human erythropoietin in children maintained by haemodialysis, J Pediatr, 117, pp. 556-560, (1990)

[6]

Bohler E., Leo A., Linderkamp O., Braun A., Scharer K., Haematological changes in uraemic children in response to erythropoietin treatment, Nephrol Dial Transplant, 8, pp. 140-145, (1993)

[7]

Van Damme-Lombaerts R., Broyer M., Businger J., Baldauf C., Stocker H., A study of recombinant human erythropoietin in the treatment of anaemia of chronic renal failure in children on haemodialysis, Paediatr Nephrol, 8, pp. 338-342, (1994)

[8]

Sinai-Trieman L., Salusky I.B., Fine R.N., Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis, J Pediatr, 114, pp. 550-553, (1989)

[9]

Warady B.A., Sabath R.J., Smith E.A., Alon U., Hellerstein S., Recombinant human erythropoietin therapy in pediatric patients receiving long term peritoneal dialysis, Pediatr Nephrol, 5, pp. 718-723, (1991)

[10]

Scharer K., Klarr B., Braun A., Dressel P., Gretz N., Treatment of renal anaemia by subcutaneous erythropoietin in children with preterminal chronic renal failure, Acta Paediatr, 82, pp. 953-958, (1993)

← 1 2 →